Help |
Site Map
|
Doris O'Brien is a retired college Speech teacher and banker. She has published two books of humor (Up or Down With Women's Liberation and Humor Me a Little) and for many years contributed light verse to the Pepper 'n Salt column of the Wall Street Journal. She is an avid writer of letters to the editors.
Doris celebrated her 50th wedding anniversary in the same year she welcomed her first grandchild. She now lives in Pasadena with a great view of the San Gabriel mountains — and the annual Tournament of Roses Parade.
She can be reached by e-mail: witsendob at (@) gmail.com
Rose Madeline Mula Writes: Why does my computer crash only when I’m behind deadline on an important project and not when I’m playing solitaire — especially since I spend much more time playing games than working. And can wine connoisseurs really detect undertones of leather, tea, oak, and dozens of other essences and aromas? When they describe a certain vintage as having “a good nose” or “legs,” are they putting me on? And when they toss out adjectives like “assertive,” “attractive,” “graceful,” and “elegant,” are they really describing the wine or the waitress pouring it? If haste makes waste, how come he who hesitates is lost? And why should we keep our noses to the grindstone if all work and no play makes Jack a dull boy? No wonder I’m an insomniac. How can I get to sleep when I keep trying to solve life’s little puzzles—like… How come the label on my sleeping pills warns, “May cause drowsiness”? Isn’t that the point? more »
Aduhelm, a new Alzheimer’s drug approved by the Food and Drug Administration last month, could be prescribed to 1 million to 2 million patients a year, even if conservative criteria were used, according to Biogen and Eisai, the companies behind the drug. The total annual price tag would come to $56 billion if the average list price, $56,000, is applied to the lower end of the companies’ estimate. That’s a huge sum by any measure — more than the annual budget for the National Institutes of Health (almost $43 billion this year). Yet there’s considerable uncertainty about Aduhelm’s clinical benefits, fueling controversy over its approval. The FDA has acknowledged it’s not clear whether the medication will actually slow the progression of Alzheimer’s disease or by how much. more »
Carol Christ: When I joined the faculty, only 3% of the faculty were women. When I joined the English department, there were 84 faculty in the English department — it was much bigger then than it is now — and there were four women. I was the fourth woman. And I remember whenever I went to an office, people didn’t believe I was a faculty member. Carol Clover: Or, when I went to Harvard, people always thought that I was a secretary in my office. They would just walk in and say, “Would you please type this for me and have it for tomorrow?” Anne Brice: What would you say? Carol Clover: It would be a nice conversation. They were usually apologetic. It was just the way things were." more »
For over fifty years, Lynn Hershman Leeson has created an innovative and prescient body of work that mines the intersections of technology and the self. Known for her groundbreaking contributions to media art, Hershman Leeson has consistently worked with the latest technologies, from Artificial Intelligence to DNA programming, often anticipating the impact of technological developments on society. As the artist posited in 1998, “Imagine a world in which there is a blurring between the soul and the chip, a world in which artificially implanted DNA is genetically bred to create an enlightened and self-replicating intelligent machine, which perhaps uses a human body as a vehicle for mobility.” more »
|
|